Top of page
Global Site Navigation

School of Medical and Health Sciences

Local Section Navigation
You are here: Main Content

Associate Professor Elin Gray

Associate Professor

Staff Member Details
Telephone: +61 8 6304 2756
Mobile: 0406 840 197
Campus: Joondalup  
Room: JO17.309  

Elin is an  Associate Professor in Cancer Research and Deputy Director of the ECU Strategic Research Centre for Precision Health. She holds a Cancer Council of Western Australia Research Fellowship, leads the Melanoma Research Group, and conducts research on the development of liquid biopsies.


Prior to appointment at ECU, Elin worked at the National Institute for Communicable Diseases in South Africa; the Vaccine Research Center at the NIH, USA and the Duke Human Vaccine Institute, Duke University, USA. Elin’s previous research focused in immunology and virology before relocating to Edith Cowan University in 2011. Associate Professor Gray's current research aims to identify blood biomarkers for diagnosis and prognosis of melanoma and other cancers to guide treatment decisions. Her team utilises and develops novel liquid biopsies through the genetic analysis of circulating tumour cells, circulating tumour DNA and extracellular vesicles, to provide information on the tumour evolution and cancer development. In addition, Elin is interested in identifying mechanisms of drug resistance and developing better treatment strategies. Associate Professor Gray works in close collaboration with leading oncologists, pathologists and industry partners to translate these results into clinical application.


  • Doctor of Philosophy, South Africa, 2008.
  • Master in Biochemistry, Cuba, 2001.
  • Bachelor of Biochemistry, Cuba, 1997.

Research Outputs

Journal Articles

  • Shyam, S., Eccles, M., Rodger, E., Pattison, S., McCall, J., Gray, E., Calapre, L., Chatterjee, A. (2021). The epigenetic landscape of circulating tumour cells. Biochimica et Biophysica Acta: Reviews on Cancer, epub ahead of print(2021), 188514.
  • Mavropalias, G., Calapre, L., Morici, M., Koeda, T., Poon, W., Barley, O., Gray, E., Blazevich, T., Nosaka, K. (2021). Changes in plasma hydroxyproline and plasma cell‑free DNA concentrations after higher‑ versus lower‑intensity eccentric cycling. European Journal of Applied Physiology, epub ahead of print(Jan), 11p..
  • Tangella, L., Arooj, M., Deplazes, E., Gray, E., Mancera, R. (2021). Identification and characterisation of putative drug binding sites in human ATP-binding cassette B5 (ABCB5) transporter. Computational and Structural Biotechnology Journal, 19(2021), 691-704.
  • Tangella, P., Clark, M., Gray, E. (2021). Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochimica et Biophysica Acta (BBA): General Subjects, 1865(1), Article number 129736.
  • Park, J., Diefenbach, R., Byrne, N., Long, G., Scolyer, R., Gray, E., Carlino, M., Rizos, H. (2021). Circulating tumor DNA reflects uveal melanoma responses to protein Kinase C inhibition. Cancers, 13(7), Article 1740.

Journal Articles

  • Khattak, M., Reid, A., Freeman, J., Pereira, M., McEvoy, A., Lo, J., Frank, M., Meniawy, T., Didan, A., Spencer, I., Amanuel, B., Millward, M., Ziman, M., Gray, E. (2020). PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. The Oncologist, 25(3), e520-e527.
  • Acheampong, E., Abed, A., Morici, M., Bowyer, S., Amanuel, B., Lin, W., Millward, M., Gray, E. (2020). Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells, 9(11), Article Number 2393.
  • Clark, M., Rizos, H., Pereira, M., McEvoy, A., Marsavela, G., Calapre, L., Meehan, K., Ruhen, O., Khattak, M., Meniawy, T., Long, G., Carlino, M., Menzies, A., Millward, M., Ziman, M., Gray, E. (2020). Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 11(44), 4016-4027.
  • Marsavela, G., Lee, J., Calapre, L., Wong, S., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Abed, A., Khattak, M., Meniawy, T., Dawson, S., Sandhu, S., Carlino, M., Menzies, A., Scolyer, R., Long, G., Amanuel, B., Millward, M., Ziman, M., Rizos, H., Gray, E. (2020). Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 26(22), 5926-5933.
  • Marsavela, G., Johansson, P., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Khattak, M., Meniawy, T., Amanuel, B., Millward, M., Hayward, N., Ziman, M., Gray, E., Calapre, L. (2020). The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection. Cancers, 12(12), Article number 3793.
  • Johansson, P., Brooks, K., Newell, F., Palmer, J., Wilmott, J., Pritchard, A., Broit, N., Wood, S., Carlino, M., Leonard, C., Koufariotis, L., Nathan, V., Beasley, A., Howlie, M., Dawson, R., Rizos, H., Schmidt, C., Long, G., Hamilton, H., Kiilgaard, J., Isaacs, T., Gray, E., Rolfe, O., Park, J., Stark, A., Mann, G., Scolyer, R., Pearson, J., Van Baren, N., Waddell, N., Wadt, K., McGrath, L., Warrier, S., Glasson, W., Hayward, N. (2020). Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 11(1), Article number 2408.
  • Aya-Bonilla, C., Morici, M., Hong, X., McEvoy, A., Sullivan, R., Freeman, J., Calapre, L., Khattak, M., Meniawy, T., Millward, M., Ziman, M., Gray, E. (2020). Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. British Journal of Cancer, 122(7), 1059-1067.
  • Warburton, L., Meniawy, T., Calapre, L., Pereira, M., McEvoy, A., Ziman, M., Gray, E., Millward, M. (2020). Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Scientific Reports, 10(1), Article number 18878.
  • Khattak, M., Abed, A., Reid, A., McEvoy, A., Millward, M., Ziman, M., Gray, E. (2020). Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. Frontiers in Oncology, 10(30 June 2020), Article number 1041.
  • Abed, A., Calapre, L., Lo, J., Correia, S., Bowyer, S., Chopra, A., Watson, M., Khattak, M., Millward, M., Gray, E. (2020). Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy. Journal for Immunotherapy of Cancer, 8(2), Article number e001620.
  • Nguyen, B., Meehan, K., Pereira, M., Mirzai, B., Lim, SH., Leslie, C., Clark, M., Sader, C., Friedland, P., Lindsay, A., Tang, C., Millward, M., Gray, E., Lim, A. (2020). A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. Scientific Reports, 10(December 2020), Article number 6083.
  • Goonoo, N., Boodhun, A., Ziman, M., Gray, E., Bhaw-Luximon, A. (2020). Repurposing nano-enabled polymeric scaffolds for tumor-wound management and 3D tumor engineering. Regenerative Medicine, 15(10), 2229-2247.
  • Lee, J., Menzies, A., Carlino, M., McEvoy, A., Sandhu, S., Weppler, A., Diefenbach, R., Dawson, S., Kefford, R., Millward, M., Al-Ogaili, Z., Tra, T., Gray, E., Wong, S., Scolyer, R., Long, G., Rizos, H. (2020). Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clinical Cancer Research, 26(15), 4064-4071.
  • Asante, D., Calapre, L., Ziman, M., Meniawy, T., Gray, E. (2020). Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. Cancer Letters, 468(1 January 2020), 59-71.
  • Scott, J., Johnston, R., Blane, S., Strickland, M., Darby, J., Gray, E. (2020). Investigating primary preservice teachers’ ultraviolet radiation awareness and perceived ability to teach sun safety. Health Promotion Journal of Australia, 2020(Article in press), 1-7.
  • Beasley, A., Bentel, J., Allcock, R., Vermeulen, T., Calapre, L., Isaacs, T., Ziman, M., Chen, F., Gray, E. (2020). Low-Pass Whole-Genome Sequencing as a Method of Determining Copy Number Variations in Uveal Melanoma Tissue Samples. The Journal of Molecular Diagnostics, 22(3), 429-434.
  • Warburton, L., Calapre, L., Pereira, M., Reid, A., Robinson, C., Amanuel, B., Ziman, M., Millward, M., Gray, E. (2020). Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. Cancers, 12(11), Article number 3486.

Journal Articles

  • Acheampong, E., Spencer, I., Lin, W., Ziman, M., Millward, M., Gray, E. (2019). Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. Cancers, 11(7), article no. 920.
  • McEvoy, A., Pereira, M., Reid, A., Pearce, R., Cowell, L., Al-Ogaili, Z., Khattak, M., Millward, M., Meniawy, T., Gray, E., Ziman, M. (2019). Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget, 10(2), 113-122.
  • Calapre, L., Giardina, T., Robinson, C., Reid, A., Al-Ogaili, Z., Pereira, M., McEvoy, A., Warburton, L., Hayward, N., Khattak, M., Meniawy, T., Millward, M., Amanuel, B., Ziman, M., Gray, E. (2019). Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Molecular Oncology, 13(2), 171-184.
  • Armitage, J., Tan, D., Cha, L., Clark, M., Gray, E., Fuller, K., Moodley, Y. (2019). A standardised protocol for the evaluation of small extracellular vesicles in plasma by imaging flow cytometry. Journal of Immunological Methods, 468(May 2019), 61-66.
  • Aya-Bonilla, C., Gray, E., Manikandan, J., Freeman, J., Zaenker, P., Reid, A., Khattak, M., Frank, M., Millward, M., Ziman, M. (2019). Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. Cancers, 11(2), Article number 157.
  • Calapre, L., Warburton, L., Millward, M., Gray, E. (2019). Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. BMC Cancer, 19(1), Article number 1109.
  • Stark, M., Gray, E., Isaacs, T., Chen, F., Millward, M., McEvoy, A., Zaenker, P., Ziman, M., Soyer, H., Glasson, W., Warrier, S., Stark, A., Rolfe, O., Palmer, J., Hayward, N. (2019). A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. Translational Vision Science and Technology, 8(6), Article 12.
  • Gray, E., Witkowski, T., Pereira, M., Calapre, L., Herron, K., Irwin, D., Chapman, B., Khattak, M., Raleigh, J., Hatzimihalis, A., Cebon, J., Sandhu, S., McArthur, G., Millward, M., Ziman, M., Dubrovic, A., Wong, S. (2019). Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. The Journal of Molecular Diagnostics, 21(3), 418-426.

Journal Articles

  • Dunkel, Y., Reid, A., Ear, J., Aznar, N., Millward, M., Gray, E., Pearce, R., Ziman, M., Ghosh, P. (2018). Prognostic relevance of CCDC88C (Daple) transcripts in the peripheral blood of patients with cutaneous melanoma. Scientific Reports, 8(1), Article number 18036.
  • McEvoy, A., Wood, B., Ardakani, N., Pereira, M., Pearce, R., Cowell, L., Robinson, C., Grieu-Iacopetta, F., Spicer, A., Amanuel, B., Ziman, M., Gray, E. (2018). Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing. The Journal of Molecular Diagnostics, 20(2), 240-252.
  • Marsavela, G., Aya-Bonilla, C., Warkiani, M., Gray, E., Ziman, M. (2018). Melanoma circulating tumor cells: Benefits and challenges required for clinical application. Cancer Letters, 424(Jun 2018), 1-8.
  • McEvoy, A., Warburton, L., Al-Ogaili, Z., Celliers, L., Calapre, L., Pereira, M., Khattak, M., Meniawy, T., Millward, M., Ziman, M., Gray, E. (2018). Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer, 18(1), Article no. 726.
  • Beasley, A., Isaacs, T., Khattak, M., Freeman, J., Allcock, R., Chen, F., Pereira, M., Yau, K., Bentel, J., Vermeulen, T., Calapre, L., Millward, M., Ziman, M., Gray, E. (2018). Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. JCO Precision Oncology, 2(May 17, 2018), 12p..
  • Zaenker, P., Lo, J., Pearce, R., Cantwell, P., Cowell, L., Lee, M., Quirk, C., Law, H., Gray, E., Ziman, M. (2018). A diagnostic autoantibody signature for primary cutaneous melanoma. Oncotarget, 9(55), 30539-30551.

Journal Articles

  • Khattak, A., Gray, E. (2017). Ipilimumab Activity in Advanced Uveal Melanoma: A Pooled Analysis. International Journal of Cancer and Clinical Research, 4(2), article no.088.
  • Calapre, L., Gray, E., Kurdykowski, S., David, A., Descargues, P., Ziman, M. (2017). SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes. BMC Dermatology, 17(June 2017), Article No. 8.
  • McEvoy, A., Calapre, L., Pereira, M., Giardina, T., Robinson, C., Khattak, M., Meniawy, T., Pritchard, A., Hayward, N., Amanuel, B., Millward, M., Ziman, M., Gray, E. (2017). Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 8(45), 78890-78900.
  • Aya-Bonilla, C., Marsavela, G., Freeman, J., Lomma, C., Frank, M., Khattak, M., Tarek, M., Millward, M., Warkiani, M., Gray, E., Ziman, M. (2017). Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget, 8(40), 67355-67368.
  • Calapre, L., Warburton, L., Millward, M., Ziman, M., Gray, E. (2017). Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 404(28 Sept, 2017), 62-69.

Journal Articles

  • Zaenker, P., Gray, E., Ziman, M. (2016). Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmunity Reviews, 15(5), 477-483.
  • Mufhandu, HT., Alexandre, KB., Gray, E., Morris, L., Khati, M. (2016). UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance. Biochemistry and Biophysics Reports, 7(1), 408-414.
  • Calapre, L., Gray, E., Kurdykowski, S., David, A., Hart, P., Descargues, P., Ziman, M. (2016). Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo. BMC Dermatology, 16(1), Article no. 6.
  • Bradley, T., Trama, A., Tumba, N., Gray, E., Lu, X., Madani, N., Jahanbakhsh, F., Eaton, A., Xia, S., Parks, R., Lloyd, KE., Sutherland, LL., Scearce, RM., Bowman, CM., Barnett, SW., Abdool-Karim, SS., Boyd, SD., Melillo, BN., Smith III, AB., Sodroski, JG., Kepler, TB., Alam, SM., Gao, F., Bonsignori, M., Liao, H., Moody, MA., Montefiori, DC., Santra, S., Morris, L., Haynes, BF. (2016). Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 12(October), 196-207.

Book Chapters

Journal Articles

  • Reid, A., Freeman, J., Millward, M., Ziman, M., Gray, E. (2015). Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clinical Biochemistry, 48(15), 999-1002.
  • Gray, E., Reid, A., Bowyer, S., Calapre, L., Siew, K., Pearce, R., Cowell, L., Frank, M., Millward, M., Ziman, M. (2015). Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. Journal of Investigative Dermatology, 135(8), 2040-2048.
  • Moody, A., Gao, F., Gurley, T., Amos, J., Kumar, A., Hora, B., Marshall, D., Whitesides, J., Xia, S., Parks, R., Lloyd, K., Hwang, K., Lu, X., Bonsignori, M., Finzi, A., Vandergrift, N., Alam, M., Ferrari, G., Shen, X., Tomaras, G., Kamanga, G., Cohen, M., Sam, N., Kapiga, S., Gray, E., Tumba, N., Morris, L., Zolla-Pazner, S., Gorny, M., Mascola, J., Hahn, B., Shaw, G., Sodroski, J., Liao, H., Montefiori, D., Hraber, P., Korber, B., Haynes, B. (2015). Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 18(3), 354-362.
  • Richardson, S., Gray, E., Mkhize, N., Sheward, D., Lambson, B., Wibmer, CK., Masson, L., Werner, L., Garrett, N., Passmore, J., Abdool Karim, Q., Abdool Karim, S., Williamson, C., Moore, P., Morris, L. (2015). South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on aα4β7 for replication. Retrovirology, 12(54), Article Number 54.
  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Siew, K., Lomma, C., Cooper, A., Khattak, M., Meniawy, T., Long, G., Carlino, M., Millward, M., Ziman, M. (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018.
  • Bandawe, G., Moore, P., Werner, L., Gray, E., Sheward, D., Madiga, M., Nofemela, A., Thebus, R., Marais, J., Maboko, L., Karim, S., Hoelscher, M., Morris, L., Williamson, C. (2015). Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. Journal of Infectious Diseases, 211(9), 1461-1466.

Conference Publications

  • Maurya, D., Fooladvand, M., Gray, E., Ziman, M., Alameh, K. (2015). Lab-on-chip platform for circulating tumor cells isolation. Micro+Nano Materials, Devices, and Systems (9668-34). SPIE.

Journal Articles

  • Klinac, D., Gray, E., Freeman, J., Reid, A., Bowyer, S., Millward, M., Ziman, M. (2014). Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 14(1), Article number 423.

Journal Articles

  • Klinac, D., Gray, E., Milward, M., Ziman, M. (2013). Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Frontiers in Oncology, 3(March 2013), Article 00054.
  • Calapre, L., Gray, E., Ziman, M. (2013). Heat stress: a risk factor for skin carcinogenesis. Cancer Letters, 337(1), 35-40.
  • Alexandre, K., Moore, P., Nonyane, M., Gray, E., Ranchobe, N., Chakauya, E., McMahon, J., O'Keefe, B., Chikwamba, R., Morris, L. (2013). Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology, 446(1-2), 66-76.
  • Lacerda, M., Moore, P., Ngandu, N., Seaman, M., Gray, E., Murrell, B., Krishnamoorthy, M., Nonyane, M., Madiga, M., Wibmer, C., Sheward, D., Bailer, R., Gao, H., Greene, K., Karim, S., Mascola, J., Korber, B., Montefiori, D., Morris, L., Williamson, C., Seoighe, C. (2013). Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virology Journal, 10(Article no. 347), 18 p..
  • Moore, PL., Sheward, D., Nonyane, M., Ranchobe, N., Hermanus, T., Gray, E., Karim, SS., Williamson, C., Morris, L. (2013). Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. Journal of Virology, 87(9), 4882-4894.
  • Wibmer, C., Bhiman, J., Gray, E., Tumba, N., Abdool Karim, SS., Williamson, C., Morris, L., Moore, P. (2013). Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathogens, 9(10), 16p..

Journal Articles

  • Mufhandu, H., Gray, E., Madiga, M., Tumba, N., Alexandre, K., Khoza, T., Wibmer, C., Moore, P., Morris, L., Khati, M. (2012). UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. Journal of Virology, 86(9), 4989-4999.
  • Archary, D., Rong, R., Gordon, M., Boliar, S., Madiga, M., Gray, E., Dugast, A., Hermanus, T., Goulder, P., Coovadia, H., Werner, L., Morris, L., Alter, G., Derdeyn, C., Ndung'u, T. (2012). Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology, 433(2), 410-420.
  • Alexandre, K., Gray, E., Mufhandu, H., McMahon, J., Chakauya, E., O'Keefe, B., Chikwamba, R., Morris, L. (2012). The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cells. Virology, 423(2), 175-186.
  • Lynch, R., Tran, L., Louder, M., Schmidt, S., Cohen, M., Dersimonian, R., Euler, Z., Gray, E., Karim, S., Kirchherr, J., Montefiori, D., Sibeko, S., Soderberg, K., Tomaras, G., Yang, Z., Nabel, G., Schultemaker, H., Morris, L., Haynes, B., Mascola, J. (2012). The Development of CD4 Binding Site Antibodies during HIV-1 Infection. Journal of Virology, 86(14), 7588-7595.
  • Moore, P., Gray, E., Wibmer, CK., Bhiman, J., Nonyane, M., Sheward, D., Hermanus, T., Bajimaya, S., Tumba, N., Abrahams, M., Lambson, B., Ranchobe, N., Ping, L., Ngandu, N., Karim, Q., Karim, S., Swanstrom, R., Seaman, M., Williamson, C., Morris, L. (2012). Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape. Nature Medicine, 18(11), 1688-1692.
  • Freeman, J., Gray, E., Milward, M., Pearce, R., Ziman, M. (2012). Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. Journal of Translational Medicine, 10(1), art. no. 192.

Journal Articles

  • Moore, P., Gray, E., Sheward, D., Madiga, M., Ranchobe, N., Lai, Z., Honnen, W., Nonyane, M., Tumba, N., Hermanus, T., Sibeko, S., Mlisana, K., Karim, S., Williamson, C., Pinter, A., Morris, L. (2011). Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. Journal of Virology, 85(7), 3128-3141.
  • Bonsignori, M., Hwang, K., Chen, X., Tsao, C., Morris, L., Gray, E., Marshall, D., Crump, J., Kapiga, S., Sam, N., Sinangil, F., Pancera, M., Yongping, Y., Zhang, B., Zhu, J., Kwong, P., O'Dell, S., Mascola, J., Wu, L., Nabel, G., Phogat, S., Seaman, M., Whitesides, J., Moody, M., Kelsoe, G., Yang, X., Sodroski, J., Shaw, G., Montefiori, D., Kepler, T., Tomaras, G., Alam, S., Liao, H., Haynes, B. (2011). Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. Journal of Virology, 85(19), 9998-10009.
  • Gray, E., Madiga, M., Hermanus, T., Moore, P., Wibmer, C., Tumba, N., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., Karim, S., Morris, L. (2011). The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4 T cell decline and high viral load during acute infection. Journal of Virology, 85(10), 4828-4840.
  • Tomaras, G., Binley, J., Gray, E., Crooks, E., Osawa, K., Moore, P., Tumba, N., Tong, T., Shen, X., Yates, N., Decker, J., Wibmer, C., Gao, F., Alam, S., Easterbrook, P., Karim, S., Kamanga, G., Crump, J., Cohen, M., Shaw, G., Mascola, J., Haynes, B., Motefiori, D. (2011). Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. Journal of Virology, 85(21), 11502-11519.
  • Morris, L., Chen, X., Alam, M., Tomaras, G., Zhang, R., Marshall, D., Chen, B., Parks, R., Foulger, A., Jaeger, F., Donathan, M., Bilska, M., Gray, E., Karim, S., Kepler, T., Whitesides, J., Montefiori, D., Moody, MA., Liao, H., Haynes, B. (2011). Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One, 6(9), Article no. e23532.
  • Gray, E., Moody, A., Wibmer, C., Chen, X., Marshall, D., Amos, J., Moore, P., Foulger, A., Yu, J., Lambson, B., Karim, S., Whitesides, J., Tomaras, G., Haynes, B., Morris, L., Liao, H. (2011). Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. Journal of Virology, 85(15), 7719-7729.
  • Alexandre, K., Gray, E., Pantophlet, R., Moore, P., McMahon, J., Chakauya, E., O'Keefe, B., Chikwamba, R., Morris, L. (2011). Binding of the mannose-specific lectin, Griffithsin, to HIV-1 gp120 exposes the CD4-binding site. Journal of Virology, 85(17), 9039-9050.

Research Projects

  • Cancer Blood Biomarkers Study - Biobank, Department of Health WA, Future Health Research and Innovation Fund - Biobank Interim Support Program 2021, 2021 ‑ 2023, $52,000.
  • Identification of melanoma-specific signature that can predict response to immunotherapies., Cancer Council of WA Inc, Suzanne Cavanagh Early Career Investigator Grants, 2021 ‑ 2023, $34,960.
  • Autoantibodies as Biomarkers of Onset of Immune-related Adverse Events in Cutaneous Melanoma Patients, Department of Health WA, Cancer and Palliative Care Network (WACPCN) Cancer Fellowship, 2021 ‑ 2022, $206,812.
  • Enabling Advanced Single Cell Cancer Genomics in Western Australia, Cancer Research Trust, The Grant, 2017 ‑ 2022, $305,925.
  • Developing blood tests to guide treatment of melanoma, Cancer Council of WA Inc, Fellowship, 2019 ‑ 2022, $955,724.
  • Exploring therapeutic targets for the treatment of metastatic uveal melanoma, Cancer Council of WA Inc, Collaborative Cancer Grant Scheme, 2021 ‑ 2022, $64,718.
  • Circulating Melanoma Cells as Predictive Biomarkers of Response to Immune Checkpoint Blockade , Cancer Council of WA Inc, Grant, 2020 ‑ 2022, $100,000.
  • Circulating tumour DNA as a biomarker of treatment response for patients with advanced high grade serous ovarian cancer receiving neoadjuvant chemotherapy with and without durvalumab and tremilimumab as part of the iprime study, Australia New Zealand Gynaecological Oncology Group (ANZGOG), Grant, 2020 ‑ 2022, $49,317.
  • Genomic HLA heterozygosity, T-cell receptor (TCR) – repertoire diversity and tumor PD-L1 expression as predictive biomarkers of response to immunotherapy in lung cancer patients, Lung Foundation Australia, Ellen Yates Memorial Grant in Aid, 2020 ‑ 2021, $20,000.
  • AMRF Early Career Researcher Grants Program, Australian Melanoma Research Foundation, 2020 Research Grant, 2020 ‑ 2021, $30,000.
  • Medical and Health Research Infrastructure Fund 2019 (Round 23), Department of Health WA, Medical and Health Research Infrastructure, 2020 ‑ 2021, $20,011.
  • Liquid Biopsy to assess microscopic residual disease in melanoma, National Health and Medical Research Council, Scholarship, 2020 ‑ 2021, $87,182.
  • Early Detection of Cancer Spread and Treatment of Ocular Melanoma, Cancer Council of WA Inc, PhD Top Up Scholarship, 2018 ‑ 2020, $30,000.
  • Early detection of uveal melanoma, Australian Melanoma Research Foundation, 2020 Research Grant, 2020, $8,500.
  • Translation of "Liquid Biopsy" Research into Clinical Practice, Western Australian Health Translation Network, Early Career Fellowships, 2019 ‑ 2020, $121,074.
  • Medical and Health Research Infrastructure Fund 2018 (Round 22), Department of Health WA, Medical and Health Research Infrastructure, 2019 ‑ 2020, $20,979.
  • Liquid biopsy for personalised monitoring of melanoma patients , National Health and Medical Research Council, Development Grants, 2017 ‑ 2020, $820,889.
  • Development of a Multiplex Test for the Early Diagnosis of Melanoma, Tour de Cure, Senior Research Grant, 2019, $280,000.
  • Predictive significance of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) and serum vascular endothelial growth factor (VEGF) in advanced melanoma patients treated with pembrolizumab, Merck Sharp and Dohme (Australia) Pty Ltd, Grant, 2016 ‑ 2019, $73,300.
  • Single Cell Whole Transcriptome Sequencing of Melanoma Circulating Tumour Cells (CTCs): Unveiling Cell Diversity, Tour de Cure, Pioneering Cancer Research Grant, 2019, $120,000.
  • Characterisation of Melanoma Circulating Tumour Cells for Personalised Treatment, Cancer Research Trust, Postdoctoral Fellowship, 2014 ‑ 2019, $980,000.
  • Medical and Health Infrastructure Fund award 2016 Round 20, Department of Health WA, Medical and Health Research Infrastructure, 2017 ‑ 2018, $19,463.
  • Understanding the Role of Melanoma Exosomes in Intercellular Communication, Cancer Council of WA Inc, Collaborative Cancer Grant Scheme, 2017 ‑ 2018, $43,230.
  • A Blood Based ‘Liquid Biopsy’ to Improve Healthcare for Metastatic Melanoma Patients, Department of Health WA, SHRAC Research Translation Projects, 2016 ‑ 2018, $218,693.
  • NHMRC Fellowship 'near-miss' funding, Department of Health WA, Near Miss Merit Awards, 2016 ‑ 2018, $50,000.
  • Circulating Tumour DNA to Predict and Monitor Treatment Response and Detect Acquired Resistance in Patients with Metastatic Melanoma, Ramaciotti Foundation, Grant, 2015 ‑ 2018, $99,911.
  • Genetic Analysis of Blood Markers for Prognosis in Patients with Uveal Melanoma, University of Western Australia, Raine Foundation Grant, 2016 ‑ 2018, $100,000.
  • Blood Based Biomarkers Predictive of Treatment Response in Melanoma, Cancer Council of WA Inc, Grant, 2016 ‑ 2018, $246,822.
  • Blood based biomarkers predictive of treatment efficacy in metastatic melanoma, Spinnaker Health Research Foundation, Collaborative Research Partnership Grants, 2017 ‑ 2018, $107,448.
  • Liquid Biopsy for Prognosis of Uveal Melanoma, The Ophthalmic Research Institute of Australia, ORIA - Grant, 2018, $27,551.
  • Using a Functional Protein Array to Identify Autoantibody Biomarkers with Diagnostic Potential for Melanoma, National Health and Medical Research Council, Development Grants, 2014 ‑ 2017, $452,058.
  • Circulating Melanoma Cells as Predictive Biomarkers of Treatment Response and Disease Status, Cancer Council of WA Inc, Grant, 2015 ‑ 2017, $111,519.
  • New Independent Research Infrastructure Support Award 2016, Department of Health WA, New Independent Researcher Infrastructure Support (NIRIS) Awards, 2016 ‑ 2017, $10,000.
  • Gene expression profiling of circulating tumour cells (CTCs) isolated from metastatic melanoma patients using a microfluidic chip, Cancer Council of WA Inc, Grant - Early Career Investigator, 2016 ‑ 2017, $35,000.
  • Western Australia Single-Cell Isolation and Genomics Preparation Facility, Australian Research Council, Grant - Linkage (Infrastructure), 2017, $430,000.
  • Circulating Tumour Cells (CTCs) as a diagnostic tool to monitor disease progression in melanoma patients, Edith Cowan University, ECU Industry Collaboration Grant - 2015 (Round 1), 2015 ‑ 2016, $25,000.
  • Mass Cytometry: A breakthrough in multidimensional systems biology, Australian Research Council, Grant - Linkage (Infrastructure), 2015 ‑ 2016, $1,081,489.
  • Transcriptomic profiling of Circulating Tumour Cells (CTCs) isolated from metastatic melanoma patients, Edith Cowan University, School of Medical and Health Sciences Research Grant Scheme 2016, 2016, $10,000.
  • A Single-Molecule Super-Resolution Microscopy Facility in Western Australia, Australian Research Council, Grant - Linkage (Infrastructure), 2016, $1,600,000.
  • Melanoma Mutation Profiling For Personalised Treatment, National Health and Medical Research Council, Project Grants, 2013 ‑ 2016, $765,359.
  • Detection of Vemurafenib Resistance in Circulating Tumour Cells for Personalised Treatment of Melanoma, Harry Perkins Institute of Medical Research, Scott Kirkbride Melanoma Research Centre - Discovery Research Priming Grant, 2013 ‑ 2014, $68,182.
  • Genetic Analysis of Melanoma Cells in Blood For Personalised Treatment Management, Edith Cowan University, ECU Early Career Researcher Grant - 2013, 2013 ‑ 2014, $24,083.
  • Expanding Capacity and Capability in Western Australian Flow Cytometry for Earth, Oceans, Environmental and Biomedical Science: State-of-the-Art Four Laser and 12 Colour Analysis, Australian Research Council, Grant - Linkage (Infrastructure), 2012 ‑ 2013, $295,000.
  • Detection of stem cell markers expression in circulating melanoma cells using multiparameter flow cytometry as a prognosis tool, Edith Cowan University, ECU Early Career Researcher Grant - 2012 (Round 1), 2012 ‑ 2013, $19,480.
  • Neon Transfection System and Biomedical Research Grade -30oC Freezer for Alzheimer’s and Melanoma Research, National Health and Medical Research Council, Equipment Grant 2011, 2011 ‑ 2012, $10,927.

Research Student Supervision

Principal Supervisor

  • Doctor of Philosophy, Blood based biomarkers of response in advanced melanoma
  • Doctor of Philosophy, Unravelling the potential applications of extracellular vesicles for the clinical management of melanoma patients
  • Doctor of Philosophy, Blood based biomarkers of response in advanced melanoma
  • Doctor of Philosophy, The use of ctcs and ctdna for the prediction and monitoring of response to combined chemotherapy and immunotherapy in high grade serous ovarian carcinoma (hgsoc)
  • Doctor of Philosophy, Assessing the clinical utility of circulating tumour cell in non-small cell lung cancer

Co-principal Supervisor

  • Master of Medical and Health Science by Research, Autoantibodies as prognostic biomarkers for cutaeous melanoma

Associate Supervisor

  • Master of Medical and Health Science by Research, Evaluating the effects of a structured exercise program on melanoma patients undergoing checkpoint inhibitor therapy
  • Doctor of Philosophy, Effect of chronic and acute exercise-induced myokines on prostate cancer cells

Principal Supervisor

  • Doctor of Philosophy, An investigation on role of the ATP-binding cassette B5 (ABCB5) transporter as potential mediator of melanoma resistance to BRAF inhibition
  • Master of Science (Medical Science), Characterizing PD-L1 expression in circulating melanoma and non-small cell lung cancer cells
  • Master of Science (Human Biology), Genetic markers in circulating tumour cells as a measure of the metastatic propensity of uveal melanoma
  • Doctor of Philosophy, Development of Novel Tests to Improve the Management of Uveal Melanoma
  • Doctor of Philosophy, Assessment of the clinical utility of ctDNA analysis for melanoma management

Associate Supervisor

  • Doctor of Philosophy, The identification and validation of a diagnostic signature of tumour-associated autoantibodies for the early diagnosis of cutaneous melanoma
  • Doctor of Philosophy, Heat stress: A risk factor for skin carcinogenesis
  • Doctor of Philosophy, Circulating tumour DNA: A non-invasive biomarker for melanoma
  • Master of Science (Human Biology), Optimisation of the isolation and identification of circulating melanoma cells
Skip to top of page